Tumor Biology

, Volume 36, Issue 5, pp 3629–3635 | Cite as

The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis

  • Malgorzata Fuksiewicz
  • Beata Kotowicz
  • Andrzej Rutkowski
  • Maria Kowalska
Research Article


The aim of this study was the evaluation of clinical usage of metalloproteinase (MMP): proMMP-1, MMP-2, MMP-7, MMP-9, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in serum of patients with rectal cancer, as well as the selection of parameters of the greatest diagnostic sensitivity and the determination of their relation with clinicopathological features, what is more, the demonstration whether their concentrations may have a prognostic value in the assessment of disease-free survival (DFS) and overall survival (OS). The study comprised 100 patients with rectal cancer including 29 women and 71 men. The tested group was comprised of qualified patients without distant metastasis (M0). It was demonstrated that in patients with rectal cancer, the concentrations of MMP-9, MMP-7, and proMMP-1 as well as TIMP-1 were significantly higher in comparison to the reference group. On the basis of ROC curves, the greatest diagnostic sensitivity of MMP-9 was demonstrated. When evaluating the correlation of tested parameters with the size of the tumor (T1–T2 vs T3–T4), essential differences were shown for proMMP-1 concentrations. The highest percentage of patients with progression had an increased concentration of MMP-7 and TIMP-1. During a 5-year follow-up, univariate log-rank analysis had shown an essential dependence between the concentration of MMP-7 in men and DSF which was confirmed in Cox multivariate analysis. It was demonstrated that the pretreatment concentration of proMMP-1 may be clinically useful when evaluating the mass of the tumor, whereas MMP-7 may be a prognostic factor for DFS in men with rectal cancer without distant metastasis.


Metalloproteinase Prognostic factor Rectal cancer Tumor 


Conflicts of interest



  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;6:1374–403.CrossRefGoogle Scholar
  2. 2.
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;12:2893–917.CrossRefGoogle Scholar
  3. 3.
    de Gramont A, de Gramont A, Chibaudel B, et al. GERCOR (French Oncology Research Group). From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol. 2011;4:521–32.CrossRefGoogle Scholar
  4. 4.
    Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;4:511–20.CrossRefGoogle Scholar
  5. 5.
    Donada M, Bonin S, Barbazza R, et al. Management of stage II colon cancer—the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 2013;13:36.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (RGTM) guidelines. Eur J Cancer. 2003;39:718–27.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokines measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor. Tumor Biol. 2005;26:186–94.CrossRefGoogle Scholar
  8. 8.
    Mroczko B, Groblewska M, Okulczyk B, et al. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis. 2010;25(10):1177–84.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.PubMedGoogle Scholar
  10. 10.
    Said A, Raufman J, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers. 2014;6:366–75.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lukaszewicz-Zajac M, Mroczko B, Guzinska-Ustymowicz K, et al. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci. 2013;58:235–43.CrossRefPubMedGoogle Scholar
  12. 12.
    Li C-Y, Yuan P, Lin S-S, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumor Biol. 2013;34:735–41.CrossRefGoogle Scholar
  13. 13.
    Polistena A, Cucina A, Dinicola S, et al. MMP7 expression in colorectal tumours of different stages. In vivo. 2014;28:105–10.PubMedGoogle Scholar
  14. 14.
    Groblewska M, Mroczko B, Gryko M, et al. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumor Biol. 2014;35:3793–80.CrossRefGoogle Scholar
  15. 15.
    Rutkowski A, Zajac L, Pietrzak L, et al. Surgical site infections following short-term radiotherapy and total mesorectal excision: results of a randomized study examining the role of gentamicin collagen implant in rectal cancer surgery. Tech Coloproctol 2014, Jul 4. [Epub ahead of print]Google Scholar
  16. 16.
    Nesteruk D, Rutkowski A, Fabisiewicz S, et al. Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data. Biomed Res Int. 2014;2014:712827.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Murray D, Morrin M, McDonnell S. Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res. 2004;24:489–94.PubMedGoogle Scholar
  18. 18.
    Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer. 2007;97:971–7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78–86.CrossRefPubMedGoogle Scholar
  20. 20.
    Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004;98:173–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Oberg A, Hoythya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085–91.PubMedGoogle Scholar
  22. 22.
    Ishida H, Murata N, Hayashi Y, et al. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today. 2003;33:885–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Holten-Andersen M, Christensen IJ, Nilbert M, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer survival. A validation study. Eur J Cancer. 2004;1:64–72.CrossRefGoogle Scholar
  24. 24.
    Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Shiozawa J, Ito M, Nakayama T, et al. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol. 2000;9:925–33.CrossRefGoogle Scholar
  26. 26.
    Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000;2:108–11.CrossRefGoogle Scholar
  27. 27.
    Bendardaf R, Buhmeida A, Ristamaki R, et al. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol. 2007;42:1473–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Langenskiöld M, Ivarsson ML, Holmdahl L, et al. Intestinal mucosal MMP-1—a prognostic factor in colon cancer. Scand J Gastroenterol. 2013;48:563–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase 7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004;64:665–71.CrossRefPubMedGoogle Scholar
  30. 30.
    Xing XJ, Gu XH, Ma TF. Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis. Tumor Biol 2014; Jul 25[Epub ahead of print]Google Scholar
  31. 31.
    Luo HZ, Zhou ZG, Yang L, et al. Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol. 2005;12:739–44.CrossRefGoogle Scholar
  32. 32.
    Pryczynicz A, Gryko M, Niewiarowska K, et al. Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer. Folia Histochem Cytobiol. 2013;51:206–12.CrossRefPubMedGoogle Scholar
  33. 33.
    Martínez-Fernandez A, García-Albeniz X, Pineda E, et al. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol. 2009;16:1412–20.CrossRefPubMedGoogle Scholar
  34. 34.
    Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121(5):1066–71.CrossRefPubMedGoogle Scholar
  35. 35.
    Yukawa N, Yoshikawa T, Akaike M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology. 2007;72:205–20.8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Malgorzata Fuksiewicz
    • 1
  • Beata Kotowicz
    • 1
  • Andrzej Rutkowski
    • 2
  • Maria Kowalska
    • 1
  1. 1.Laboratory of Tumor Markers, Department of Pathology and Laboratory DiagnosticsMaria Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsawPoland
  2. 2.Department of Oncological GastroenterologyMaria Sklodowska-Curie Memorial Cancer Centre and Institute of OncologyWarsawPoland

Personalised recommendations